Clinical trials: Autosomal Dominant Polycystic Kidney
Polycystic Kidney, Autosomal Dominant
The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease
There are substantial data demonstrating increased endothelial dysfunction, inflammation and oxidative stress in patients with Autosomal dominant polycystic kidney disease (ADPKD), the association between serum uric acid level…
- Trial name
- NCT01589705
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- TC Erciyes University
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common hereditary renal disease, responsible for 8% to 10% of the cases of end stage renal disease (ESRD) in Western countries.
- Trial name
- ALADIN (NCT00309283)
- Testing
- Long-acting somatostatin, Saline solution
- Where
- 5 sites in Italy
- Volunteers
- 78 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Autosomal Dominant Polycystic Kidney Disease, Nephrogenic Diabetes Insipidus
Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration
The purpose of this research is to study the effectiveness and safety of the medication PB in slowing the frequent urination related to tolvaptan as long-term treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), or…
- Conditions
- Autosomal Dominant Polycystic Kidney Disease, Nephrogenic Diabetes Insipidus, Acquired Nephrogenic Diabetes Insipidus, Congenital Nephrogenic Diabetes Insipidus
- Trial name
- SerendipityPB1 (NCT05190744)
- Testing
- PB
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Bempedoic Acid Therapy for Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease (ADPKD), the most commonly inherited kidney disease, is characterized by the development of cysts in the kidney that impair function.
- Trial name
- BEAT-PKD (NCT07282821)
- Testing
- Bempedoic Acid 180 MG Oral Tablet
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Kenneth Hallows
ADPKD
Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?
The investigators are running a study to see if a special drink, called a "ketone ester", can help people with a type of kidney disease named "Autosomal Dominant Polycystic Kidney Disease" or ADPKD for short.
- Trial name
- ADKETONE (NCT06100133)
- Testing
- Ketone ester
- Volunteers
- 20 people
- Sponsor
- Universitair Ziekenhuis Brussel
Polycystic Kidney, Autosomal Dominant, Chronic Kidney Diseases
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease
The ability to concentrate and dilute urine is primarily regulated via vasopressin (AVP) dependent Aquaporin-2 water channels (AQP2 channels) in the kidney's collecting duct.
- Trial name
- POVA (NCT04363554)
- Testing
- Fluid intake, Thirsting
- Where
- Denmark
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Regional Hospital Holstebro
Polycystic Kidney Diseases
Everolimus on CKD Progression in ADPKD Patients
The study will evaluate whether the administration of everolimus (1.5 mg/day) can slow down the progression of CKD in ADPKD patients.
- Trial name
- NCT01009957
- Testing
- Everolimus
- Where
- 7 sites in Italy
- Volunteers
- 71 people
- Sponsor
- A. Manzoni Hospital
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Study of Tamibarotene in Patients With ADPKD
Clinical trial of tamibarotene in patients with Autosomal Dominant Polycystic Kidney Disease
- Trial name
- NCT06289998
- Testing
- Tamibarotene
- Where
- 8 sites in Japan
- Volunteers
- 70 people
- Sponsor
- Rege Nephro Co., Ltd.
Autosomal Dominant Polycystic Kidney
Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
The EMPA-PKD trial is assessing the safety of empagliflozin in patients with rapid progressive ADPKD with and without concomitant tolvaptan use by monitoring kidney growth and the rate of loss of kidney function.
- Trial name
- EMPA-PKD (NCT06391450)
- Testing
- Empagliflozin 10 MG
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Hannover Medical School
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE, norethindrone (NET) and EE and drospirenone (DRSP) and EE.
- Trial name
- NCT07074327
- Testing
- VX-407, LNG/EE, NGM/EE
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Polycystic Kidney Disease, Adult, Polycystic Kidney, Autosomal Dominant
PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)
Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic cause of end-stage kidney disease (ESKD). The disorder is characterized by development and continued growth of multiple cysts requiring renal…
- Trial name
- PENGUIN (NCT04407481)
- Testing
- Aminohippurate Sodium Inj 20%, Iohexol Inj 300 milligrams per milliliter (MG/ML), PET/CT Scan
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Colorado, Denver
Autosomal Dominant Polycystic Kidney Disease
High Water Intake in Polycystic Kidney Disease
DRINK is an open-label randomised controlled feasibility trial of high versus ad libitum water intake in ADPKD.
- Trial name
- DRINK (NCT02933268)
- Testing
- High water intake, Ad libitum water intake
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Chronic Renal Failure, Polycystic Kidney Disease
Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease
This study was designed to provide confirmation of safety of mesenchymal stem cells (MSCs) therapy in chronic renal failure due to autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT02166489
- Testing
- Intravenous injection autologous mesenchymal stem cells
- Where
- Iran
- Volunteers
- 6 people
- Sponsor
- Royan Institute
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
To collect characteristics of patients with ADPKD across a broad population, over time to better understand disease progression (signs, symptoms and outcomes).
- Trial name
- OVERTURE (NCT01430494)
- Where
- 266 sites in United States, Argentina and 18 more
- Volunteers
- 3,409 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Polycystic Kidney, Autosomal Dominant, ADPKD
Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt
This study evaluates the effect of regulating salt and protein intake on urinevolume in patients with ADPKD treated with a vasopressine V2 receptor antagonist (V2RA).
- Conditions
- Polycystic Kidney, Autosomal Dominant, ADPKD, Autosomal Dominant Polycystic Kidney
- Trial name
- WATER (NCT04310319)
- Testing
- Sodiumchloride, Protein
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Esther Meijer
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.
- Trial name
- AGLOW (NCT07161037)
- Testing
- VX-407
- Where
- 43 sites in United States, Belgium and 6 more
- Volunteers
- 26 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Autosomal Dominant Polycystic Kidney, Overweight and Obesity
Daily Caloric Restriction in ADPKD
This clinical trial will determine whether a daily-caloric restriction-based weight loss intervention can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese.
- Trial name
- NCT04907799
- Testing
- Daily caloric restriction, Standard advice control
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- University of Colorado, Denver
Polycystic Kidney Diseases
Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
This study is a prospective, randomized, open-label, pilot clinical trial designed to compare the effects of an agent that has antiproliferative (1,2), antiangiogenesis (3),and tumor-progression blocking capabilities (4), namely…
- Trial name
- NCT00286156
- Testing
- Rapamune
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Polycystic Liver Disease
Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).
This Pilot study will enable development \& assessment of a Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q).
- Trial name
- NCT02173080
- Testing
- PLD-Q
- Where
- United States
- Volunteers
- 594 people
- Sponsor
- Mayo Clinic
ADPKD
Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping
This is a retrospective analysis to include demographic, clinical, biochemical, and genetic data that will further explore the natural history of ADPKD and assess the factors that are likely to be associated with the progression…
- Trial name
- ADPKD (NCT02161068)
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- The Rogosin Institute